Back to today’s briefing

Story perspectives

FDA Approves Groundbreaking ALS Gene Therapy Trial

4/1/2025

50 10

Summary

Story summary

The FDA has given the green light for Sineugene Therapeutics to launch a Phase 1/2a trial of SNUG01, a groundbreaking gene therapy targeting amyotrophic lateral sclerosis (ALS). By boosting TRIM72 protein levels, this innovative treatment could slow the relentless progression of ALS, offering hope where few options exist. Early studies indicate promising safety and efficacy, marking a significant step forward in ALS care.

1 of 1

Story summary

The FDA has given the green light for Sineugene Therapeutics to launch a Phase 1/2a trial of SNUG01, a groundbreaking gene therapy targeting amyotrophic lateral sclerosis (ALS). By boosting TRIM72 protein levels, this innovative treatment could slow the relentless progression of ALS, offering hope where few options exist. Early studies indicate promising safety and efficacy, marking a significant step forward in ALS care.